We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Archives Journals |

Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy

Michael P. Heffernan, MD; Kenneth G. Saag, MD, MSc; June K. Robinson, MD; Jeffrey P. Callen, MD
JAMA. 2006;295(11):1300-1303. doi:10.1001/jama.295.11.1300.
Text Size: A A A
Published online


Sulzberger MB, Witten VH, Yaffe SN.Cortisone acetate administered orally in dermatologic therapy. Arch Dermatol Syphilol. 1951;64:573-578
Link to Article[[XSLOpenURL/10.1001/archderm.1951.01570110043006]]
Michel BA, Bloch DA, Wolfe F, Fries J.Fractures in rheumatoid arthritis. J Rheumatol. 1993;20:1666-1669
Ray NF, Chan JK, Thamer M, Melton LJ III.Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995. J Bone Miner Res. 1997;12:24-35
PubMed   |  Link to Article[[XSLOpenURL/10.1359/jbmr.1997.12.1.24]]
Chrischilles EA, Butler CD, Davis CS, Wallace RB.A model of lifetime osteoporosis impact [published correction appears in Arch Intern Med. 1922;152:655]. Arch Intern Med. 1991;151:2026-2032
PubMed   |  Link to Article[[XSLOpenURL/10.1001/archinte.1991.00400100100017]]
Center JR, Nguyen TV, Schneider D, Sambrook PM, Eisman JA.Mortality after all major types of osteoporotic fracture in men and women. Lancet. 1999;353:878-882
PubMed   |  Link to Article[[XSLOpenURL/10.1016/S0140-6736(98)09075-8]]
Hannan EL, Magazine J, Wan JJ.  et al. Mortality and locomotion 6 months after hospitalization for hip fracture. JAMA. 2001;285:2736-2742
PubMed   |  Link to Article[[XSLOpenURL/10.1001/jama.285.21.2736]]
Trombetti A, Herrmann F, Hoffmeyer P.  et al. Survial and potential years of life lost after hip fracture in men and aged-matched women. Osteoporos Int. 2002;13:731-737
PubMed   |  Link to Article[[XSLOpenURL/10.1007/s001980200100]]
Johnell O, Kanis JA, Oden A.  et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15:38-42
PubMed   |  Link to Article[[XSLOpenURL/10.1007/s00198-003-1490-4]]
Miller W.Survival and ambulation following a hip fracture. J Bone Joint Surg Am. 1978;60A:930-934
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646-650
PubMed   |  Link to Article[[XSLOpenURL/10.1016/0002-9343(93)90218-E]]
Bonar SK, Teinetti ME, Speechley M, Cooney LM.Factors associated with short- and long-term skilled nursing facility placement among community-living hip fracture patients. J Am Geriatr Soc. 1990;38:1139-1144
Van Staa T, Leufkens HGM, Abenhaim L, Zhang B, Cooper C.Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000
PubMed   |  Link to Article[[XSLOpenURL/10.1359/jbmr.2000.15.6.993]]
Rehman Q, Lane NE.Effect of glucocorticoids on bone density. Med Pediatr Oncol. 2003;41:212-216
PubMed   |  Link to Article[[XSLOpenURL/10.1002/(ISSN)1096-911X]]
van Staa TP, Leufkens HG, Cooper C.The epidemiology of corticosteroid-induced osteoporosis. Osteoporos Int. 2002;13:777-787
PubMed   |  Link to Article[[XSLOpenURL/10.1007/s001980200108]]
Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat SM, Setoain J.Vertebral fractures in steroid dependent asthma and involutional osteoporosis. Thorax. 1991;46:803-806
PubMed   |  Link to Article[[XSLOpenURL/10.1136/thx.46.11.803]]
American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996;39:1791-1801
PubMed   |  Link to Article[[XSLOpenURL/10.1002/(ISSN)1529-0131]]
Adachi JD, Olszynski WP, Hanley DA.  et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228-251
PubMed   |  Link to Article[[XSLOpenURL/10.1016/S0049-0172(00)80011-6]]
Sambrook PN, Diamond T, Ferris L.  et al. Osteoporosis Australia; National Asthma Campaign. Corticosteroid induced osteoporosis. Aust Fam Physician. 2001;30:793-796
Adler RA, Hochberg MC.Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med. 2003;163:2619-2624
PubMed   |  Link to Article[[XSLOpenURL/10.1001/archinte.163.21.2619]]
Geusens PP, de Nijs RN, Lems WF.  et al. Prevention of glucocorticoid osteoporosis. Ann Rheum Dis. 2004;63:324-325
PubMed   |  Link to Article[[XSLOpenURL/10.1136/ard.2003.008060]]
Lester RS, Sandra RK, Neil HS.The risks of systemic corticosteroid use. Dermatol Clin. 1998;16:277-286
da Silva JA, Jacobs JW, Kirwan JR.  et al. Low-dose glucocorticoid therapy in rheumatoid arthritis. Ann Rheum Dis. 2006;65:285-293
PubMed   |  Link to Article[[XSLOpenURL/10.1136/ard.2005.038638]]
Summey BT, Yosipovich G.Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol. 2006;142:82-90
PubMed   |  Link to Article[[XSLOpenURL/10.1001/archderm.142.1.82]]
Saag KG, Emkey R, Schnitzer TJ.  et al. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292-299
PubMed   |  Link to Article[[XSLOpenURL/10.1056/NEJM199807303390502]]
Cohen S, Levy RM, Keller M.  et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum. 1999;42:2309-2318
PubMed   |  Link to Article[[XSLOpenURL/10.1002/(ISSN)1529-0131]]
Lane NE, Sanchez S, Modin GW.  et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest. 1998;102:1627-1633
PubMed   |  Link to Article[[XSLOpenURL/10.1172/JCI3914]]
Liu RH, Albrecht J, Werth VP.Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol. 2006;142:37-41
Link to Article[[XSLOpenURL/10.1001/archderm.142.1.37]]
Lozsadi DA, Peters G, Sadik HY.  et al. Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg. 2006;108:157-162
Link to Article[[XSLOpenURL/10.1016/j.clineuro.2005.05.008]]
Walsh LJ, Wong CA, Pringle M, Tattersfield AE.Use of oral corticosteroids in the community and the prevention of secondary osteoporosis. BMJ. 1996;313:344-346
PubMed   |  Link to Article[[XSLOpenURL/10.1136/bmj.313.7053.344]]
Ip M, Larn K.Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;105:1722-1727
PubMed   |  Link to Article[[XSLOpenURL/10.1378/chest.105.6.1722]]
Solomon DH, Katz JN, La Tourette AM, Coblyn JS.Multifaceted intervention to improve rheumatologists' management of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2004;51:383-387
PubMed   |  Link to Article[[XSLOpenURL/10.1002/(ISSN)1529-0131]]
Naunton M, Peterson GM, Jones G.  et al. Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol. 2004;31:550-556
Kiefe CI, Allison JJ, Williams OD.  et al. Improving quality improvement using achievable benchmarks for physician feedback. JAMA. 2001;285:2871-2879
PubMed   |  Link to Article[[XSLOpenURL/10.1001/jama.285.22.2871]]
Edge JC, Outland JD, Dempsey JR, Callen JP.Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65-69
PubMed   |  Link to Article[[XSLOpenURL/10.1001/archderm.142.1.65]]
Hantash B, Fiorentino D.Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch Dermatol. 2006;142:109-110
PubMed   |  Link to Article[[XSLOpenURL/10.1001/archderm.142.1.109]]
Enk AH, Knop J.Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;135:54-56
PubMed   |  Link to Article[[XSLOpenURL/10.1001/archderm.135.1.54]]
Mimouni D, Anhalt GJ, Cummins DL.  et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139:739-742
PubMed   |  Link to Article[[XSLOpenURL/10.1001/archderm.139.6.739]]
Bystryn JC, Steinman NM.The adjuvant therapy of pemphigus: an update. Arch Dermatol. 1996;132:203-212
PubMed   |  Link to Article[[XSLOpenURL/10.1001/archderm.1996.03890260105016]]
Burruss JB, Farmer ER, Callen JP.Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol. 1996;35:720-724
PubMed   |  Link to Article[[XSLOpenURL/10.1016/S0190-9622(96)90727-6]]


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

8 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.